Innovative Microfluidics Spindiag's proprietary microfluidic platform LabDisk enables the development of compact, automated point-of-care diagnostic systems, offering a unique opportunity to target healthcare providers seeking rapid and reliable infectious disease testing solutions.

Rapid COVID-19 Testing With the launch of its coronavirus rapid test system capable of delivering results within 40 minutes, Spindiag has established a strong positioning in the urgent market for quick, on-site viral diagnostics, ideal for hospitals, clinics, and testing centers.

Recent Funding Momentum Having secured over $15 million in funding, including recent investments of $3.28 million and EUR 6 million from government sources, Spindiag is positioned to scale its innovative diagnostic products and expand market reach.

Focus on Infectious Diseases Spindiag’s emphasis on developing sustainable, fully automated diagnostic platforms for bacterial and viral pathogens, including drug-resistant strains, aligns with increasing global demand for reliable infectious disease testing.

Small-Scale Growth Despite limited employee size, Spindiag’s strategic focus on innovative solutions and recent funding rounds make it a compelling partner for collaborations, OEM opportunities, or solution integrations in the rapidly growing diagnostics market.